This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John P. Phair, MD

JAMA. 1994;271(14):1121-1122.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since the introduction of zidovudine, an inhibitor of retroviral reverse transcriptase, there has been continuing controversy regarding the usefulness of this agent. Questions have been raised about the optimal time to initiate therapy and about the duration of benefit achieved with this form of antiretroviral treatment. Preliminary findings of the Concorde trial,¹ a multicenter double-blind, randomized study, failed to demonstrate a significant benefit in survival or rate of disease progression in patients with immediate use of zidovudine therapy compared with deferred treatment. The guidelines promulgated by the expert panel convened after the results of the Concorde trial were presented attempted to address these issues using data from controlled clinical trials.² The panel suggested that antiretroviral therapy was optional in asymptomatic persons with CD4 lymphocyte counts of 0.20 to 0.50X10⁹/L (200 to 500/µL) but that zidovudine should be given to human immunodeficiency virus (HIV)-infected individuals who were . . . [Full Text PDF of this Article]

Author Affiliations
From the Comprehensive AIDS Center, Northwestern University School of Medicine, Chicago, Ill.

Footnotes
Reprint requests to Comprehensive AIDS Center, Northwestern University School of Medicine, 680 N Lake Shore Dr, Suite 1106, Chicago, IL60611 (Dr Phair).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?